Cognitive & Neuroprotection
Cerebrolysin
Last updated
Dosing on file unverified
IV: 10-50 mL/day diluted in saline, 10-21 day cycles; IM: up to 5 mL/day; Stroke: 30-50 mL/day; AD: 10-60 mL/day
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Literature on file 8
-
human observational
Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. graded on: a synthesis of human studies — “Systematic Review”
-
human RCT
NCT00947531: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia graded on: randomised and placebo-controlled — “Randomized, Double-blind, Placebo-controlled”
-
human RCT
NCT00911807: A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD) graded on: a randomised trial — “Randomized, Double-Blind, Clinical Trial”
-
human RCT
NCT02149875: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study. graded on: a randomised study — “Randomized, Double-blind Study”
-
human RCT
NCT00840671: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke graded on: a randomised trial — “Randomised, Placebo Controlled, Double Blind Trial”
-
human observational
NCT01388738: Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. graded on: a registered clinical study — “clinicaltrials.gov”
Not graded
2 citations whose study design could not be read from the title. Left ungraded rather than guessed at.
- not graded
- not graded
Notes unverified prose
Approved in >50 countries; 398-patient AIS study used 20 mL IV infusions; TBI study used 30 mL/day IV for 10 days; AD trial used 10, 30, or 60 mL IV; multiple RCTs
Not on file 8
8 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.
- molecular weightnothing we hold supplies it
- molecular formulanothing we hold supplies it
- CAS registry numbernothing we hold supplies it
- PubChem identifiernothing we hold supplies it
- amino-acid sequencenot applicable to this compound
- SMILES stringnothing we hold supplies it
- InChInothing we hold supplies it
- InChI keynothing we hold supplies it
Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.